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ABSTRACT 
Colesevelam was originally approved for the treatment of hyperlipidaemia (high blood lipids) 
in the 2000s but has been shown to improve blood sugar as well. Therefore, we investigated 
its role in the management of type 2 diabetes mellitus. A total of 1450 patients took part in 
six studies investigating colesevelam. These studies lasted 8 to 26 weeks. Only one small 
study compared colesevelam directly to placebo, the other five studies investigated a 
combination of colesevelam with other antidiabetic agents versus a combination of placebo 
with other antidiabetic agents. There were no two studies with the same intervention and 
comparison group. When added to other antidiabetic agents colesevelam showed 
improvements in the control of blood glucose and blood lipids. However, it is difficult to 
disentangle the effects of colesevelam from the other antidiabetic agents used because only 
one study compared colesevelam to placebo. The same is true for adverse effects: three 
studies reported on just a few non-severe hypoglycaemic episodes, no other serious side 
effects were observed. No study investigated mortality; complications of type 2 diabetes such 
as eye disease, kidney disease, heart attack and stroke; health-related quality of life; 
functional outcomes and costs of treatment. Therefore, long-term data on the efficacy and 
safety of colesevelam are necessary. 
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